Recently, Kirtane et al. hypothesized that the presence of fibrin in the tumor ECM contributes to the impaired intratumoral distribution of nanoscale drugs and the use of a fibrinolytic enzyme, such as tissue plasminogen activator (tPA), can overcome the poor distribution from nanocarriers4. Here, PLAT is linked to neoplasm.